|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In summary, the present study has provided further evidence that knockdown of PFTK1 inhibited the proliferation and invasion of pancreatic cancer cells as well as the EMT progress by suppressing the PI3K/Akt signaling pathway.
|
26823712 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In summary, we report that small interfering RNA (siRNA)-PFTK1 might inhibit the proliferation and invasion of NSCLC cells by suppressing the Wnt/β-catenin signaling pathway.
|
27458099 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Expressions of downstream molecules in Wnt signaling pathway as well as the proliferation, invasion and migration ability of the SKOV3 cells were reduced when CDK14 was inhibited (all p < 0.05).
|
27505004 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, our findings suggest a mechanism by which DYRK2 controls CDK14 expression to regulate tumor cell proliferation and invasion in breast cancer.
|
29193658 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, knockdown of PFTK1 attenuated cell proliferation, anchorage-independent cell growth, and cell migration and invasion by inhibiting the transcriptional activation of β-catenin for cyclin D1, MMP9, and HEF1, whereas exogenous expression of PFTK1 might promote MDA-MB-231 cells proliferation, migration, and invasion via promoting PFTK1-DVL2-β-catenin axis.
|
26033031 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We showed in PFTK1-suppressed cells that knockdown of TAGLN2 over-rode the inhibitory effect on cell invasion and motility, and a recovery on actin polymerization was evident.
|
21577206 |
2011 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Knocking PFTK1 down by small interfering RNA (siRNA) significantly inhibited ovarian cancer cell proliferation, migration and invasion.
|
26772918 |
2016 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
However, the essential role of CDK14 and the molecular mechanisms by which miRNAs regulate CDK14 in the oncogenesis and progression of OS have not been fully elucidated.
|
29022909 |
2017 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223.
|
30119217 |
2018 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In summary, these data prove that LINC00858/miR-139/CDK14 axis promotes the tumorigenesis of osteosarcoma, providing a new mechanism or target for osteosarcoma.
|
29944887 |
2018 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer.
|
30557834 |
2019 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Cyclin Y (CCNY) is a newly identified PFTK1 interacting protein and has been found to be associated with the proliferation and tumorigenesis of human non-small cell lung cancer.
|
27666310 |
2016 |
|
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer.
|
30474270 |
2019 |
|
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Therefore, these findings reveal that PFTK1 might potentially become a novel strategy for targeting pancreatic cancer.
|
26823712 |
2015 |
|
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
MiR-431 inhibits cell proliferation and induces cell apoptosis by targeting CDK14 in pancreatic cancer.
|
30058687 |
2018 |
|
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
|
30915884 |
2019 |
|
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
|
30915884 |
2019 |
|
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
MiR-431 inhibits cell proliferation and induces cell apoptosis by targeting CDK14 in pancreatic cancer.
|
30058687 |
2018 |
|
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
Therefore, these findings reveal that PFTK1 might potentially become a novel strategy for targeting pancreatic cancer.
|
26823712 |
2015 |
|
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer.
|
30474270 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our findings suggest a mechanism by which DYRK2 controls CDK14 expression to regulate tumor cell proliferation and invasion in breast cancer.
|
29193658 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our finding revealed miR-455 inhibits breast cancer cell proliferation through targeting CDK14, it might be a target for breast cancer therapy.
|
28300591 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Our findings supported the notion that up-regulated PFTK1 might promote breast cancer progression and metastasis by activating Wnt signaling pathway through the PFTK1-DVL2-β-catenin axis.
|
26033031 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Long non-coding RNA SNHG15 promotes CDK14 expression via miR-486 to accelerate non-small cell lung cancer cells progression and metastasis.
|
29630731 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Cyclin Y (CCNY) is a newly identified PFTK1 interacting protein and has been found to be associated with the proliferation and tumorigenesis of human non-small cell lung cancer.
|
27666310 |
2016 |